Article Details

Aridis Pharmaceuticals (NASDAQ:ARDS) Stock Rating Reaffirmed by Maxim Group

Retrieved on: 2022-08-18 07:47:30

Tags for this article:

Click the tags to see associated articles and topics

Aridis Pharmaceuticals (NASDAQ:ARDS) Stock Rating Reaffirmed by Maxim Group. View article details on HISWAI: https://www.etfdailynews.com/2022/08/18/aridis-pharmaceuticals-nasdaqards-stock-rating-reaffirmed-by-maxim-group/

Excerpt

Vanguard Group Inc. now owns 524,122 shares of the company's stock valued at $922,000 after buying an additional 16,785 shares in the last quarter.

Article found on: www.etfdailynews.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up